<DOC>
	<DOC>NCT02764229</DOC>
	<brief_summary>The purpose of this study is to allow subjects completing study LYC-30937-2001 the opportunity to receive LYC-30937-EC 25 mg.</brief_summary>
	<brief_title>Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis</brief_title>
	<detailed_description>Subjects who complete the 8 week treatment period of the double-blind, placebo-controlled study LYC-30937-2001 will have the option of receiving LYC-30397-EC 25 mg PO QD in this open-label extension study (LYC-30937-2002). Subjects meeting eligibility criteria will enter this open-label extension trial upon completion of the LYC-30937-2001 Week 8 study procedures. This open-label extension study will consist of 44 weeks of treatment followed by a 2 weeks post-treatment follow-up.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Completed the 8week doubleblind treatment period of study LYC309372001 Male and females of childbearing potential must agree to use adequate birth control during the study and for 30 days after discontinuing study drug Nonpregnant, nonlactating females who are not planning to become pregnant while enrolled in this study Investigator considers it safe and potentially beneficial to participate Ability to provide written informed consent and to be compliant with study schedule Subjects who completed study LYC309372001, but who experienced a serious adverse event that was considered related to investigational product, has an unstable medical condition, or for any other reason in the opinion of the investigator should not participate in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>